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Guide to Clinical Trials
B. Spilker, New York: Raven Press, 1991, 1156 pp. $162.50.
This enormous single author book is written to explain the
practical details of clinical trials. The 133 chapters cover the
details of trial design, writing a protocol, aspects of statistics,
the interpretation of response and efficacy data, how to
publish results and the regulatory and managerial aspects of
trials.
Within the chapters Dr Spilker tries to explain the basic
principles of what is to be discussed or investigated and to
give a flow diagram or table of how to go about getting the
data, or analysing it. He writes clearly but the text is often
rather tediously generalised so that, for example, in the dis-
cussion of trial size there is a brief resume of a and P errors,
but little insight into how the trial size relates to the clinical
importance of the question (whether, for example, the size of
any difference needs to be quantified precisely). There is little
insight into the importance of statistical methodology
generally. Some of the chapters appear strangely out of
place. There are for example 33 pages on preparing an article
for publication and assessing the quality of a paper you have
read. Much of this consists ofpages of tables. There is a long
series of chapters on the goals and strategies of marketing
and drug development which may be of interest to phar-
maceutical companies but seem somewhat beside the point
for clinicians.
Almost everything and anything to do with trials is
touched on in this book. That is both a strength and a
weakness. I suppose that the professional group who would
find it most valuable are the clinical co-ordinators of research
in pharmaceutical companies, especially in the USA (there
are concessions to regulatory authorities elsewhere in the
world). I don't really recommend it for oncologists involved
in trials since it is not detailed enough in certain key areas
and contains much information and advice which is redun-
dant for cancer trials.
R.L. Souhami
Introducing New Treatment for Cancer. Practical, Ethical and
Legal Problems
Edited by C.J. Williams, Chichester: John Wiley & Sons,
1992, 492 pp. £24.95.
This book is long overdue. There can be few investigators
involved in testing new cancer treatments who have not been
concerned by at least some of the many difficult problems
discussed. The international list of contributors include
lawyers, ethicists, social scientists, statisticians, phar-
macologists, editors of medical journals, physicians working
for pharmaceutical companies, radiotherapists, medical
oncologists and specialists in community care. The book is
divided into five sections. Section 1 deals with legal (UK and
international) and ethical aspects of clinical trials and with
patients' attitudes to such therapy. In addition there are
chapters on informed consent, research ethics committees
and a summary of the Royal College of Physicians report on
Research Involving Patients. Informed consent comes up
again in Section 2 which discusses specific issues in trials of
new cancer treatments including the question of whether
patients in trials do better than those treated routinely. There
are chapters on phase I studies, 'the uncertainty principle'
design for randomised trials, randomisation before consent
(Zelen) designs, interim analysis and experiments on the
dying. Section 3 considers the pharmaceutical industry's role
and economic issues. Section 4 discusses trials for pre-
malignant lesions and chemoprevention trials and the final
section concerns itself with reporting policies, overviews and
the adoption of new treatments into clinical practice. Prior to
each section the editor, Chris Williams, gives a very helpful
outline of the areas to be discussed. Here he does not merely
summarise the views expressed, but focuses the more impor-
tant elements as well as voicing personal views which may
not always coincide with those of the chapter authors. This
serves as a most refreshing highlight to the controversial
aspects, particularly those surrounding informed consent.
The story of the reaction of the late Dr Franz Ingelfinger
(editor of the New England Journal of Medicine) on learning
that he had oesophageal cancer illustrates beautifully the
important difference between what the cancer patient may
want in terms of information and what others believe he
should have. For this experienced physician his illness was
much easier to cope with when he found a more traditionally
paternalistic doctor who was prepared to make the treatment
decisions for him. In section 2, various specific problem areas
are covered. For example, in his introduction the editor
touches on the difficulty of testing new drugs in chemosen-
sitive tumours. If one uses the new drug first and it turns out
to be ineffective then there will be a delay in introducing
standard effective treatment and drug resistance may be
induced. On the other hand if one waits till the patient no
longer responds to standard treatment, then multiple drug
resistance may have developed and the true efficacy of the
new drug will not emerge. Williams suggests that trials
should randomise patients to the new drug followed by the
phase II drug on progression. This is a very unwieldy solu-
tion which would not provide any general truths about the
safety or not of using new drugs in previously untreated
patients and could not possibly be repeated for each drug
because of the large number of patients that would be
required. Unfortunately this problem is not developed further
in the book and is the principal omission in what is otherwise
a comprehensive examination of the dilemmas facing new
cancer drug investigators. Section 3 deals with the phar-
maceutical industry and economic considerations. It is the
weakest section. The chapter on economic evaluation of
cancer treatments is, in places, banal (e.g. Figure 2), in others
confusing ('The efficacy and effectiveness of chemotherapy in
solid tumours are ambiguous'), and in others still poorly
described (Figure 4). A discussion of the implications for
governments struggling to finance ever more costly health
care is lacking. At the end of each chapter there is a useful
brief biography ofthe authors and a reference list. The text is
well laid out and a reasonably comprehensive index has been
compiled. Dr Williams is to be congratulated on assembling
an intriguing list of authors who have put together a fas-
cinating book which, although not offering any particularly
novel solutions to the many problems involved in the int-
roduction of new cancer treatments, certainly has them dis-
cussed clearly and, for the first time, grouped in a single text.
M.H. Cullen
Breast Cytology in Clinical Practice
S. Catania & S. Ciatto, London: Martin Dunitz, 1991,
136 pp. £39.95.
Fine needle aspiration cytology is used increasingly in the
investigation and management of breast disease, and to be
successful, requires the combined skills of clinician,
radiologist and cytopathologist.
First published in Italy, in 1989, this book is particularly
directed to the practical problems of obtaining material from
breast lesions and providing adequate preparations for cyto-
pathological evaluation. There is useful discussion of the role
of the cytopathologist, with guidance on the interpretation
and practical application of results. Although mainly con-
cerned with FNA, the indications for examination of cyst
fluids and nipple discharge are also presented in the light of
considerable clinical experience.
In addition the 14 sections (120 pages) with references and
illustrations cover a number of other aspects, including
historical background, physical examination of the breast,
use of ultrasound and stereotaxis, and the measurement of
oestrogen-receptor content. Possible hazards of needle aspira-